Mwandishi:
Mhariri:
Imeboershwa:
ULY CLINIC
ULY CLINIC
10 Julai 2026, 11:01:06
Stevens Johnson Syndrome (SJS)
Stevens–Johnson Syndrome (SJS) is a rare but serious acute mucocutaneous hypersensitivity reaction, most commonly triggered by medications. It is characterized by epidermal necrosis leading to blistering and detachment of the skin and mucous membranes.
SJS represents the milder end of the SJS/TEN spectrum:
SJS: <10% body surface area detachment
SJS/TEN overlap: 10–30%
TEN: >30%
This condition is a medical emergency due to risk of dehydration, sepsis, and organ failure.
Etiology
Drug-induced (most common)
Sulfonamides
Anticonvulsants (carbamazepine, phenytoin, phenobarbital, lamotrigine)
Allopurinol
Nevirapine
NSAIDs (oxicam group)
Penicillins and cephalosporins
Infectious triggers (more common in children)
Mycoplasma pneumoniae
Viral infections (HSV, HIV)
Pathophysiology
Immune-mediated cytotoxic reaction:
Drug antigen activates cytotoxic T-cells
Keratinocyte apoptosis occurs
Epidermis separates from dermis
Leads to blistering and erosions of skin and mucosa
Risk Factors
HIV infection
Previous drug reactions
Polypharmacy
Genetic susceptibility (HLA-related)
Malignancy
Autoimmune disease
Signs and Symptoms
Prodromal phase (1–3 days)
Fever
Malaise
Arthralgia
Sore throat
Burning eyes
Cutaneous findings
Abrupt erythema multiform-like rash
Target lesions evolving to blisters
Skin tenderness
Peeling epidermis
Mucosal involvement
Oral
Painful erosions
Hemorrhagic crusted lips
Necrotic white pseudomembrane
Ocular (70–90%)
Erosive conjunctivitis
Photophobia
Risk of corneal scarring
Genital (60–70%)
Painful erosions
Dysuria
Diagnostic Criteria
Clinical diagnosis based on:
Sudden erythema multiform-like rash
Prodrome with fever, malaise, arthralgia
Hemorrhagic crusted lips and oral erosions
Eye involvement (erosive conjunctivitis)
Genital mucosal erosions
Skin detachment <10% BSA
Investigations
Laboratory tests
Full blood count
Urea and electrolytes
Liver function tests
Blood glucose
CRP
Infection assessment
Blood cultures if febrile
Swabs from erosions
Confirmatory test
Skin biopsy → epidermal necrosis
Treatment
Admission and Monitoring
Immediate hospital admission
Close monitoring of fluids and electrolytes
Nutritional support
Temperature regulation
Non-Pharmacological Treatment
Stop suspected drug immediately
Maintain hydration
Gentle wound care (non-adhesive dressings)
Oral care with saline rinses
Eye lubrication and ophthalmology review
Prevent secondary infection
Pain control
Pharmacological Treatment
Hydrocortisone (IV) 200 mg every 12 hours for 48 hours
AND
Prednisolone (PO) 1–2 mg/kg once daily for 5–7 days
AND
Administer appropriate antibiotics only if secondary infection or sepsis is present, following the recommended treatment for sepsis.
Supportive management
Identify and immediately discontinue the suspected offending medication or drug.
Transfer the patient to an Intensive Care Unit (ICU), Critical Care Unit, or Burn Unit where available.
Provide appropriate wound care.
Keep the patient warm.
Monitor fluid input and output, aiming for a urine output of at least 0.5 mL/kg/hour.
Monitor electrolytes regularly.
Obtain consultations with an Ophthalmologist, Physician, and Dermatologist.
SCORTEN score (Prognostic assessment)
Assess the following risk factors:
Age >40 years
Presence of malignancy
Total body surface area affected >10%
Heart rate >120 beats/minute
Blood urea nitrogen >28 mg/dL
Serum glucose >250 mg/dL
Serum bicarbonate <20 mEq/L
Calculate the SCORTEN score on Days 1 and 3 of hospital admission to determine prognosis.
Important notes
Avoid topical sulfur-containing medications.
If systemic corticosteroids are used, they should be initiated within the first 24 hours of disease onset to help abort the immunologic reaction. Delayed initiation may increase the risk of infection and delay healing.
Complications
a. Acute
Dehydration
Sepsis
Electrolyte imbalance
Pneumonia
b. Long-term
Ocular scarring → blindness
Genital adhesions
Chronic dry eyes
Skin pigmentation changes
Prevention
Avoid re-exposure to culprit drug
Record allergy in medical file
Patient drug-alert card
Careful prescribing in HIV patients
Pharmacovigilance reporting
Imeandikwa;
3 Novemba 2020, 15:38:00
